✦ LIBER ✦

Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study

✍ Scribed by Christoph Mamot; Reto Ritschard; Andreas Wicki; Gregor Stehle; Thomas Dieterle; Lukas Bubendorf; Christoph Hilker; Stefanie Deuster; Richard Herrmann; Christoph Rochlitz

Book ID: 118267286
Publisher: The Lancet
Year: 2012
Tongue: English
Weight: 262 KB
Volume: 13
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(12)70476-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A dose escalation and pharmacokinetic st

A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours

✍ Bozionelou, V; Vamvakas, L; Pappas, P; Agelaki, S; Androulakis, N; Kalykaki, A; 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 113 KB

A phase 1 open-label, sequential dose-es

A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors

✍ Ghamande, Sharad; Lin, Chia-Chi; Cho, Daniel C.; Shapiro, Geoffrey I.; Kwak, Eun 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 318 KB

A phase I dose escalation study of the p

A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours

✍ Edwina N. Scott; Anne L. Thomas; L. Rhoda Molife; Samreen Ahmed; Sarah Blagden; 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 253 KB

A phase I dose-escalation study to evalu

A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer

✍ Desar, I M E; Timmer-Bonte, J N H; Burger, D M; van der Graaf, W T A; van Herpen 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 349 KB

A Phase Ib dose-escalation study to eval

A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours

✍ van Herpen, C M L; Eskens, F A L M; de Jonge, M; Desar, I; Hooftman, L; Bone, E 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 306 KB

423 Phase 1 dose escalation, safety and

423 Phase 1 dose escalation, safety and pharmacokinetic study of IT-101 (CRLX101), a novel nanopharmaceutical containing camptothecin, in advanced solid tumor cancer patients

✍ Y. Yen; T. Synold; G.J. Weiss; T. Schluep; J. Ryan 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 82 KB